News

Science-Based Medicine2dOpinion
With Laura Loomer on One Side and Dr. Paul Offit on the Other, Our FDA Leaders are Caught in a Trap of Their Own Making
After years of bashing the medical establishment, Drs. Vinay Prasad and Marty Makary are stuck in a trap. Any attempt to ...
Opinion
MAHA proves health reform doesn’t need red tape
MAHA is proving that voluntary cooperation beats regulation when it comes to fixing America's broken health and food systems.
100 days into the job, FDA head talks to CNN about agency goals— and Coke’s switch to sugar
Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and ...
Wellbeing Whisper on MSN3d
Why Most Americans Will Skip COVID Boosters—and What That Means for Public Health
We want to know more about what these products are doing,” said Dr. Vinay Prasad in a recent FDA livestreamed presentation. The statement is made as there has been a significant policy shift in the U.
The Obvious Reason the U.S. Should Not Vaccinate Like Denmark
For the best immunization policy, they argue, the U.S. should look to Europe. Marty Makary, the new FDA commissioner, and ...
Science-Based Medicine3dOpinion
FDA Has Replaced its Leadership With Doctors Who Have Done Their “Research”
A large tertiary care center in Sydney, Australia is pulling out all the stops to try and cut their expenses. As of next ...
MedPage Today3d
Kennedy's mRNA Moves Anger MAHA Allies; Winning Back NIH Grants; Start-Up Games HSAs
Mary Talley Bowden, MD, founder of Americans for Health Freedom, an advocacy group that has lobbied against mRNA shots, ...
BioSpace4d
FDA Opens Pilot Run of Commissioner Voucher Program
The FDA will select at most five companies that align with national priorities, including lower drug prices and increased ...
RFK Jr. Turns to Fringe Medical Journal to Find New Hires
George Tidmarsh is a millionaire co-founder of a biotech firm, serial entrepreneur, neonatologist and adjunct professor at ...
FDA taps new leader for drug program
The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency's drug program, the latest in a string of leadership changes at the agency.